The kind of dish that makes you want to friend your local butcher.
I feel kinda cheesy. I admit it, I feel cool about using a butcher. I understand this is lame and that butchers have been around for ages, but, truthfully, in the recent year, we?ve really gotten to know our neighborhood butchers. Growing up in the ?burbs, meat was only bought pre-cut and pre-packaged. Yes, every once in awhile you?d see the grocery store?s butcher come out from behind those weird black, plastic doors with the small square window.
Skip to next paragraph Jonny and Amy Seponara-Sills
Amy and Jonny Seponara-Sills (Amy?s American, Jonny?s English) run the food blog We Are Never Full. Through recipes, anecdotes and podcasts, it chronicles their borderline obsession with food from meals made at home to travels studiously built around the search for authentic regional and national dishes from all over the world.
Recent posts
After our first attempt at making homemade sausage, I realized how invaluable a butcher is. We live in a country where many people don?t know what kind of animal their meat comes from. Hold up an eggplant to a 10-year old and good chance they may not even know what the hell it is. It?s sad that the neighborhood butcher is starting to become a thing of the past. I live in Brooklyn, NY, one of the most multicultural places on earth and, in my 'hood alone we only have a few butchers left. I?m talking about the neighborhood butcher, not that gourmet food store up the street. You know the place ? the guy/gal behind the counter has butchers hands and fingers, you know his/her name and he/she knows your name, they don?t switch employees as quickly as McDonald?s and they can easily ask you if you want ?the regular." Word is that the decline in these gems is because young people aren?t interested in carrying on the family trade. Maybe with this economic downward spiral Americans will be more willing to work with their hands again and see the beauty how happy meat/poultry can make people.
Jonny and I have wanted to try and make a dish that we ate in Florence, Italy at the awesome Coco Lezzone since the last time we recreated their Pappa al Pomodoro. It was one of those meals from start to finish that will forever stay etched in my mind. Saveur did a cover story on their Herb-Stuffed Pork Loin in their April 2006 issue. We tweaked the recipe just a bit (lavender wasn?t a part of the original recipe) and, thanks to our awesome butcher, the dish turned out phenomenally.
Coco Lezzone's Herb and Lavendar-Stuffed Pork Loin Rib Roast Serves 6
1 6-rib center-cut pork loin roast (about 4-5 lbs) 6 cloves of garlic, peeled and ground to a paste 2 tablespoons of chopped rosemary 3 tablespoons of chopped sage 2 tablespoons of thyme 1 tablespoon dried lavender 2 tablespoons + 1/4 (or so) cup olive oil salt and pepper
Preheat over to 475 degrees F.
In a small bowl, add together the garlic, all the herbs and lavender with a pinch of salt and pepper and 2 tablespoons olive oil. Use a fork to make sure it?s all incorporated together.
Push the handle of a long wooden spoon through the center of one end of the pork roast allowing it to poke through the other end?s center. Do this again, moving the handle back and forth and in a circular motion to allow the hole to get bigger. It will end up being about 3/4 of an inch wide.
Reserve about 3/4 of a tablespoon of the herb mixture to be use in a moment. Using your fingers, push some of the herb/garlic mixture into the center hole starting on one side and the finishing on the other. Put roast in a roasting pan.
Pour about 1/4 cup or so of olive oil over the roast. Rub it in a bit. Using the reserved herb mixture, rub all around the top and sides of the rib roast. Season generously with salt and pepper and roast the pork in the oven until golden brown ? about 25 to 30 minutes. Reduce the oven to 350 degrees and continue to roast for an hour longer or until the internal temperature is 160 degrees.
Allow pork to rest about 10 minutes and then carve into individual chops. Serve with the pan drippings (which are DEEE-LISH, by the way!).
Related post: Beef Carbonnade
The Christian Science Monitor has assembled a diverse group of food bloggers. Our guest bloggers are not employed or directed by The Monitor and the views expressed are the bloggers' own and they are responsible for the content of their blogs and their recipes. All readers are free to make ingredient substitutions to satisfy their dietary preferences, including not using wine (or substituting cooking wine) when a recipe calls for it. To contact us about a blogger, click here.
Source: www.moreover.com --- Wednesday, December 28, 2011 MOSCOW President Dmitri A. Medvedev has responded to the street protests in Moscow with proposals for political reform, but his recent personnel appointments seem to tell a different story: top posts went to former officers in the K.G.B. and long-serving ...
It seems Roleplaying has changed alot over recent years, genres like Anime, romance and modern style 'Teen' RP's have grown in popularity while the Older school of good ole fantasy style Hack 'N' slash through a dungeon full of Horrors on some quest for a bag of gold and a pint of ale seem to be on the decline!
In fact these days I find I have almost stopped Roleplaying altogether, being a more 'Classic Style' fan of the Fantasy genre, the Stories that got me into Roleplaying in the first place seem to have all but vanished-
However I still feel there's much fun to be had in getting a group of adventurers together in a seedy, Medieval style Tavern and setting out on a quest to change, conquor or save the world!
So I'm looking to get just such an RP started, I have a land to set it in and am thinking of a broad, sprawling adventure full of possibilities, adventure and danger!
I was thinking recent games and Films like Skyrim or the new Conan may have interested a new generation of Roleplayers in the style, or perhaps inspired some of the older adventurers with a desire to dust off their swords, either way, all are welcome providing they can stick to the basic rules and common courtesies of Roleplaying.
More information is available, I'm just doing a quick interest check at the moment, but if anyone out there is interested in stepping into a whole new world to cross swords with a band of savage Greenskins or a deranged Necromancer bent on World Domination and Immortality, just say the word!
Thanks for reading.
Rill.
'I had to be a Warrior, a slave I could not be! A Soilder and a Conqueror, fighting to be free!'
Cela fait un bout de temps que je suis un fid?le de la pomme, question de design, rapidit?, simplicit? et applications et clairement, avant le GS2, aucun t?l?phone ne pouvait concurrencer l'iPhone. Envie de changer, envie d'un ?cran plus grand, et pas envie d'attendre l'iPhone 5. Me voil? donc face au S2 qui est joli, plus grand... et avec un Android Market presque aussi complet que l'Apple Store. Mes iPhone ont toujours ?t?s jailbreak?s sinon je vois pas l'utilit? de mettre 650? l? dedans
J'ai doncquelques questions avant de me lancer et quitter la ptite pomme :
- Existe t'il un tweak type SBsetting afin de passer en mode avion/couper la wifi en un touch?? - Existe t'il BiteSMS sur android? (Appli pour les SMS, avec photo contact, cacher des conversations etc) - Y'a t'il une appli de correction automatique comme la native sur l'iPhone pour les texte ?crits? - Peut-on remplacer le clavier natif android par celui de l'iPhone? (je trouve les touches mieux espac?es, plus sensibles, plus simples sur l'iPhone)
Autres questions :
-Avez-vous une id?e de quand sortira le S3 ? et quels caract?ristiques sont pr?vus? -Je suis chez Bouygues, et souhaite passer chez orange, ? votre avis, est-il possible de "ruser" le syst?me en prenant un forfait ? 60? par mois pour avoir le t?l?phone pour une mis?re et baisser le forfait ? 30? par mois le mois suivant en changeant d'offre?
Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase IbPublic release date: 27-Dec-2011 [ | E-mail | Share ]
Contact: Deanne Eagle deanneeagle@gmail.com 917-837-5866 Neuralstem, Inc.
First neuroregenerative drug tested in depression
ROCKVILLE, Maryland, December, 27, 2011 Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD as well as other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).
"We are pleased to be approved to begin testing NSI-189 in patients who suffer from depression," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "Loss of hippocampal volume is a known characteristic in depressed patients. NSI-189 stimulates neurogenesis and increases hippocampal volume in healthy adult mice, at the same time reversing behavioral symptoms in mouse depression models, so it could address depression at the source."
"It is exciting to see a new class of drugs that potentially offers a novel and different approach to this disease moving into patients," said Maurizio Fava, MD, Slater Family Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital. Dr. Fava, one of the world's leading researchers in MDD, helped design the Neuralstem trial.
About NSI-189
Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. It is also implicated in several major neurological and psychiatric diseases. From its hippocampal neural stem cell lines, Neuralstem has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.
Neuralstem has been engaged in its own drug discovery program with these human hippocampal stem cell lines since 2000. In 2009, Neuralstem was granted U.S. patents on four first-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models, above and beyond the neural stem cells' innate differentiation.
NSI-189 is the lead compound in Neuralstem's neuroregenerative small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric disorders, such as Alzheimer's disease, anxiety, bipolar disorder and post traumatic stress disorder.
NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).
About the Trial
The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-189 in healthy patients. Phase Ib will test the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients. The Phase Ib portion of the trial is expected to take approximately six months to complete.
###
About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.
For more information, please go to www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the quarterly report on Form 10-Q for the period ended September 30, 2011.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase IbPublic release date: 27-Dec-2011 [ | E-mail | Share ]
Contact: Deanne Eagle deanneeagle@gmail.com 917-837-5866 Neuralstem, Inc.
First neuroregenerative drug tested in depression
ROCKVILLE, Maryland, December, 27, 2011 Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD as well as other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).
"We are pleased to be approved to begin testing NSI-189 in patients who suffer from depression," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "Loss of hippocampal volume is a known characteristic in depressed patients. NSI-189 stimulates neurogenesis and increases hippocampal volume in healthy adult mice, at the same time reversing behavioral symptoms in mouse depression models, so it could address depression at the source."
"It is exciting to see a new class of drugs that potentially offers a novel and different approach to this disease moving into patients," said Maurizio Fava, MD, Slater Family Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital. Dr. Fava, one of the world's leading researchers in MDD, helped design the Neuralstem trial.
About NSI-189
Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. It is also implicated in several major neurological and psychiatric diseases. From its hippocampal neural stem cell lines, Neuralstem has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.
Neuralstem has been engaged in its own drug discovery program with these human hippocampal stem cell lines since 2000. In 2009, Neuralstem was granted U.S. patents on four first-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models, above and beyond the neural stem cells' innate differentiation.
NSI-189 is the lead compound in Neuralstem's neuroregenerative small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric disorders, such as Alzheimer's disease, anxiety, bipolar disorder and post traumatic stress disorder.
NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).
About the Trial
The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-189 in healthy patients. Phase Ib will test the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients. The Phase Ib portion of the trial is expected to take approximately six months to complete.
###
About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.
For more information, please go to www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the quarterly report on Form 10-Q for the period ended September 30, 2011.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 27-Dec-2011
Share ]